Evidence map›Paper›PMID 37052300›Full record

ReviewThe Biochemical journal2023

The biology and type I/III hybrid nature of type I-D CRISPR-Cas systems.

Tess M McBride, Shaharn C Cameron, Peter C Fineran, Robert D Fagerlund

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Biochemical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Tess M McBrideDepartment of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin 9054, New Zealand.ORCID 0000-0002-1663-4206
Shaharn C CameronDepartment of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin 9054, New Zealand.ORCID 0000-0002-5564-7034
Peter C FineranDepartment of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin 9054, New Zealand.ORCID 0000-0002-4639-6704
Robert D FagerlundDepartment of Microbiology and Immunology, University of Otago, PO Box 56, Dunedin 9054, New Zealand.ORCID 0000-0002-3939-1489

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prokaryotes have adaptive defence mechanisms that protect them from mobile genetic elements and viral infection. One defence mechanism is called CRISPR-Cas (clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins). There are six different types of CRISPR-Cas systems and multiple subtypes that vary in composition and mode of action. Type I and III CRISPR-Cas systems utilise multi-protein complexes, which differ in structure, nucleic acid binding and cleaving preference. The type I-D system is a chimera of type I and III systems. Recently, there has been a burst of research on the type I-D CRISPR-Cas system. Here, we review the mechanism, evolution and biotechnological applications of the type I-D CRISPR-Cas system.

Indexed as

CRISPR-Associated ProteinsCRISPR-Cas SystemsBiologyCRISPR-Associated ProteinsbacteriophagesCRISPRprotein structureRNA-binding proteins

Identifiers

PMID37052300
PMCPMC10212523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.